Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Even under statin therapy achieving low-density lipoprotein cholesterol control, substantial residual cardiovascular risk persists.
“Importantly, even under statin therapy achieving low-density lipoprotein cholesterol (LDL-C) control, substantial residual cardiovascular risk persists, largely attributable to elevated triglycerides (TG) and triglyceride-rich lipoprotein (TRL) remnants, including non–HDL-C and apolipoprotein B (apoB) (Watts et al., 2023; Vasas et al., 2024; Hussain et al., 2020; Malick et al., 2023a).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Vasas et al., 2024
The residual cardiovascular risk under statin therapy is largely attributable to elevated triglycerides and triglyceride-rich lipoprotein remnants, including non-HDL-C and apolipoprotein B.
“Importantly, even under statin therapy achieving low-density lipoprotein cholesterol (LDL-C) control, substantial residual cardiovascular risk persists, largely attributable to elevated triglycerides (TG) and triglyceride-rich lipoprotein (TRL) remnants, including non–HDL-C and apolipoprotein B (apoB) (Watts et al., 2023; Vasas et al., 2024; Hussain et al., 2020; Malick et al., 2023a).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Vasas et al., 2024
Cites
Still being checked.
Cited by
Sorted by citations
Gao, Y., Bai, Y., Mu, X., & Pang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736821 · Cited by 4 · see citing works
“…control, substantial residual cardiovascular risk persists, largely attributable to elevated triglycerides (TG) and triglyceride-rich lipoprotein (TRL) remnants, including non–HDL-C and apolipoprotein B (apoB) (Watts et al., 2023; Vasas et al., 2024; Hussain et al., 2020; Malick et al., 2023a).”
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 3 · see citing works
Wadehra, S., Singh, S., Kaur, S., Kaur, A., & Singh, T. G. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10649-4 · Cited by 1 · see citing works
- Authors
- Vasas, S., Azizad, M., Clifton, P., Rosenson, R., Gaudet, D., Hellawell, J., Chang, T., Melquist, S., Fu, R., Mushin, M., Martin, J. S., & Ballantyne, C.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 18
- Issue
- 4
- Pages
- e560
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W4400959548
- Cited by
- 3
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of clinical lipidology (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- plozasiran, siRNA, mixed dyslipidemia, triglycerides, remnant cholesterol, TG-rich lipoproteins, atherogenic lipoproteins, non-HDL cholesterol, apolipoprotein B, HDL cholesterol, residual cardiovascular risk, safety and tolerability, subcutaneous administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
